The upper ECHELON against T-cell lymphoma

Despite years of fierce attempts to alter the dreadful outcome of peripheral T-cell lymphoma (PTCL), therapeutic improvement over the last two decades has been disappointing. While major steps forward were being made in the B-cell lymphoma field with rituximab, Bruton tyrosine kinase inhibitors, chimeric antigen receptor T cells, and bi-specific antibodies, PTCL was way behind those breakthroughs. Most recent randomized trials in the first-line setting failed to demonstrate superiority of new chemotherapy regimens or of so-called targeted agents (e.g.